The FDA regulates stem cell and exosome products in the United States. Some clinics may falsely advertise that it is not necessary for FDA to review and approve their stem cell therapies.Dec 19, 2019
The FDA regulates stem cell and exosome products in the United States. Some clinics may falsely advertise that it is not necessary for FDA to review and approve their stem cell therapies. They may claim that their registration with FDA or an FDA inspection equates to FDA approval or a form of FDA endorsement. These claims are false.
Clinics often advertise that they are conducting clinical trials using these products. Patients should ask clinics for documentation from FDA that they are conducting a clinical trial under an active investigational new drug application, also known as an IND. Patients should always be wary if a clinic advertises a patient-funded clinical trial.
Therapeutic Solutions International, Inc. | Medical & health
Facebook https://www.facebook.com › tsoihome MCB was established in August 2023 and our estimate is next August 2024 we will have adequately aged the cells to obtain clearance for phase 3 IND @TradersTrader;-)RyanGirvan ...